Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Multiple Sclerosis |
Free Subscription
1 Int J Neurosci |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Multiple Sclerosis is free of charge.
Cross-sectional, comparative study of health-related quality of life across the
adult lifespan in multiple sclerosis.
Int J Neurosci. 2024 Mar 5:1-10. doi: 10.1080/00207454.2024.2327404.
PubMed
Abstract available
CRL4b Inhibition Ameliorates Experimental Autoimmune Encephalomyelitis
Progression.
J Immunol. 2024 Jan 24:ji2300754. doi: 10.4049/jimmunol.2300754.
PubMed
Abstract available
Altered immune co-inhibitory receptor expression and correlation of LAG-3
expression to disease severity in NMOSD.
J Neuroimmunol. 2024;388:578289.
PubMed
Abstract available
The cognitive relevance of non-lesional damage to cortical networks in people
with multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
PubMed
Abstract available
Sex impacts treatment decisions in multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
PubMed
Abstract available
Evaluation of a self-administered iPad((R))-based processing speed assessment for
people with multiple sclerosis in a clinical routine setting.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
PubMed
Abstract available
Extended interval dosing strategies in multiple sclerosis: insights from
natalizumab and ocrelizumab trials.
J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
PubMed
Early intensive versus escalation treatment in patients with relapsing-remitting
multiple sclerosis in Austria.
J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
PubMed
Abstract available
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple
sclerosis over age 60.
J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883.
PubMed
Abstract available
Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T
MRI.
J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332566.
PubMed
Abstract available
Efficacy and safety results after >3.5 years of treatment with the Bruton's
tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term
follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid
sub-study.
Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
PubMed
Abstract available
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple
sclerosis.
Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
PubMed
Abstract available
Expert opinion on the use of contraception in people with multiple sclerosis.
Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
PubMed
Abstract available
Mitochondrial DNA marks multiple sclerosis.
Nat Rev Neurol. 2024 Mar 5. doi: 10.1038/s41582-024-00948.
PubMed
MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
Neurology. 2024;102:e209199.
PubMed
Abstract available
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in
Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
Neurology. 2024;102:e208114.
PubMed
Abstract available
Psychometric evaluation of the 5-item Medication Adherence Report Scale
questionnaire in persons with multiple sclerosis.
PLoS One. 2024;19:e0294116.
PubMed
Abstract available
Fatal natalizumab-associated progressive multifocal leukoencephalopathy with
initial low JCV antibody index in a multiple sclerosis patient.
Rev Neurol (Paris). 2024 Feb 29:S0035-3787(24)00371.
PubMed
Thank you for your interest in scientific medicine.